These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37378639)

  • 41. The selective 5-HT
    Jensen AA; Halberstadt AL; Märcher-Rørsted E; Odland AU; Chatha M; Speth N; Liebscher G; Hansen M; Bräuner-Osborne H; Palner M; Andreasen JT; Kristensen JL
    Biochem Pharmacol; 2020 Jul; 177():113979. PubMed ID: 32298690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
    Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
    Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
    Hubbard D; Hacksell U; McFarland K
    Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
    Stahl SM
    CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dementia-related psychosis and the potential role for pimavanserin.
    Cummings JL; Devanand DP; Stahl SM
    CNS Spectr; 2022 Feb; 27(1):7-15. PubMed ID: 32811586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol.
    Baltzersen OB; Meltzer HY; Frokjaer VG; Raghava JM; Baandrup L; Fagerlund B; Larsson HBW; Fibiger HC; Glenthøj BY; Knudsen GM; Ebdrup BH
    Front Pharmacol; 2020; 11():591. PubMed ID: 32425802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice.
    Dashtipour K; Gupta F; Hauser RA; Karunapuzha CA; Morgan JC
    Parkinsons Dis; 2021; 2021():2603641. PubMed ID: 33489083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
    Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ
    Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-clinical pharmacology and toxicology studies of LPM6690061, a novel 5-hydroxytryptamine (5-HT)
    Zhu X; Yang Y; Du G; Liu B; Yu X; Ye L; Mao Y; Wang H; Tian J
    Food Chem Toxicol; 2023 Jun; 176():113800. PubMed ID: 37100235
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inverse agonism and its therapeutic significance.
    Khilnani G; Khilnani AK
    Indian J Pharmacol; 2011 Sep; 43(5):492-501. PubMed ID: 22021988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trial of Pimavanserin in Dementia-Related Psychosis.
    Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
    N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Opposite alterations of 5-HT
    Diez-Alarcia R; Muguruza C; Rivero G; García-Bea A; Gómez-Vallejo V; Callado LF; Llop J; Martín A; Meana JJ
    Transl Psychiatry; 2021 May; 11(1):302. PubMed ID: 34016955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of serotonin 5-HT2A receptors in memory and cognition.
    Zhang G; Stackman RW
    Front Pharmacol; 2015; 6():225. PubMed ID: 26500553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review.
    Rissardo JP; Durante Í; Sharon I; Fornari Caprara AL
    Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy.
    Marek GJ
    Curr Pharm Des; 2015; 21(26):3788-96. PubMed ID: 26044978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 5‑Hydroxytryptamine 2A receptor inverse agonist pimavanserin impairs maternal behavior in postpartum female rats.
    Gan L; Sun M; Chen W
    Pharmacol Biochem Behav; 2018 Dec; 175():152-159. PubMed ID: 30393120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature.
    Touma KTB; Touma DC
    Ment Health Clin; 2017 Sep; 7(5):230-234. PubMed ID: 29955528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
    Price DL; Bonhaus DW; McFarland K
    Behav Pharmacol; 2012 Aug; 23(4):426-33. PubMed ID: 22750845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.